Mr Ho Sheng
Mr Ho Sheng was first appointed as a Director of the Company in July 2011 and was last re-elected on October 16, 2015.
Mr Ho has more than 25 years of experience in the financial services industry and extensive experience in market cycles and exposure to regional equity markets. He is currently the Non-Executive Chairman and Independent Director of New Silkroutes Group Limited, a Singapore Exchange listed company. He was the Independent Director at Ying Li International Real Estate Limited and the Senior Vice President, Investments at Citigroup Global Markets. Prior to joining Citigroup, Mr Ho was a shareholder, Executive Director and Board Member of the stockbroking unit of UBS Warburg.
Mr Ho holds a Master of Applied Finance from Macquarie University, Sydney. He is a Senior Associate of the Financial Services Institute of Australasia and an Associate of the Institute of Chartered Secretaries and Administrators (UK).
Dr Ho Choon Hou
Dr Ho Choon Hou was first appointed as a Director of the Company in June 2011 and was last re-elected on October 18, 2013. Dr Ho is currently a Principal at Southern Capital Group Limited where he is responsible for the origination and execution of investments
Dr Ho is an Independent Director of both Advanced Holdings Limited and Mclean Berhad, and the Non-Independent Non-Executive Director and Chairman of Stemlife Berhad, a subsidiary of Cordlife Group Limited.
Dr Ho graduated with a Bachelor of Medicine and Bachelor of Surgery (Honours) from the University of Sheffield, as well as a Master of Medicine (Surgery) from the National University of Singapore and a Master of Business Administration (Honours) from the University of Chicago (Graduate School of Business).
Dr Wong Chiang Yin
Dr Wong Chiang Yin was appointed as Executive Director and Group Chief Executive Officer of the Company on July 1, 2016. As Executive Director and Group Chief Executive Officer, Dr Wong is responsible for identifying and implementing company-wide business growth strategies and organisational structures, and directly oversees all aspects of the Group’s growth and operating functions.
Dr Wong is a medical doctor as well as a public health specialist who has more than 20 years of healthcare management experience. Dr Wong was most recently the Executive Director and Group CEO of TMC Life Sciences Bhd., a healthcare company listed on the mainboard of Bursa (i.e. the Malaysia Stock Exchange). He was concurrently the President of Thomson International, the international arm of Thomson Medical Centre - Singapore’s largest private sector obstetrics and gynaecology hospital.
Between 2008 and 2009, Dr Wong was the Executive Director and CEO of the Hospitals Division in Pantai Holdings Berhad. Prior to joining the private sector in 2008, he was the Chief Operating Officer of Changi General Hospital and Singapore General Hospital, as well as the Director of Business Development, SingHealth. Dr Wong has held, and still holds, leadership positions in various medical professional bodies. He has been a council member of the Singapore Medical Association for over 20 years, and served as its President from 2006 to 2009. He has also been a council member of the Academy of Medicine Singapore since 2009.
Dr Wong is currently an Independent Director of Beng Kuang Marine Limited, a company listed on the Singapore Exchange and the Chairman of its Audit Committee. He is the Chairman of the Citizens’ Consultative Committee of the Holland-Bukit Timah Group Representation Constituency, Cashew Division.
Dr Wong graduated with a Bachelor of Medicine and Bachelor of Surgery degree, as well as a Master of Medicine (Public Health) from the National University of Singapore. In addition, he received his Master of Business Administration (Finance) from the University of Leicester. He is also a Fellow of the Academy of Medicine, Singapore.
Mr Michael Steven Weiss
Mr Michael Steven Weiss was appointed as an Executive Director, Business Development and Mergers & Acquisitions on February 1, 2017. In this role, he is responsible for all aspects of strategic acquisitions including identifying and reviewing potential mergers, acquisitions and corporate development opportunities as well as driving inorganic growth strategies. He was previously a Non-Independent Non-Executive Director of the Company.
Mr Weiss has over 18 years of experience in the finance and investment sectors in the United States and Asia, and has worked on numerous merger and acquisition transactions with many Chinese companies, including China Development Bank Capital, China Resources Gas, China Southern Grid, SinoTruk etc. Prior to Cordlife Group, Mr Weiss was a Partner and Managing Director at Chinese cross-border private equity firm, Sailing Capital. He also served as Managing Director of Morgan Stanley's China mergers advisory unit and had held investment banking positions at Credit Suisse Group AG and Citigroup Inc. Mr Weiss is also currently acting as a consultant to Sanpower Group for their cross-border investment activities.
Mr Weiss obtained his Master of Arts in Regional Studies-East Asia, focusing on Chinese business history, from Harvard University. He also holds a Bachelor degree in East Asian Studies from Northwestern University.
Dr Goh Jin Hian
Dr Goh Jin Hian was first appointed as a Director of the Company in July 2011 and was last re-elected on October 17, 2014.
Prior to this, he held several senior executive positions in Parkway Holdings Ltd (now IHH Ltd) from 1999 to 2011, including Chief Executive Officer of Gleneagles Hospital, President of Singapore Operations and Senior Vice-President of Growth, Innovation & Strategy. He served as Executive Consultant of ParkwayHealth, Singapore from April 2011 to March 2015.
Dr Goh assumed the position of Chief Executive Officer and Director of New Silkroutes Group Limited, a company listed on the Singapore Exchange, on July 7, 2015. The company is an investment holding company with interests in the energy, technology and healthcare sectors.
Dr Goh obtained his Bachelor of Medicine and Bachelor of Surgery from the National University of Singapore in 1992. He also holds a Master of Business Administration from the University of Hull. In addition, Dr Goh completed the Wharton Advanced Management Program in 2005.
Mr Joseph Wong Wai Leung
Mr Joseph Wong Wai Leung was appointed as an Independent Director of the Company on September 23, 2014 and was last re-elected on October 17, 2014.
Mr Wong has a wealth of experience in the financial services industry. He started his career at Big Four auditing firms PricewaterhouseCoopers and Deloitte Touche Tohmatsu, Hong Kong. At Deloitte, he was engaged in a wide spectrum of business domains, including but not limited to, initial public offerings, taxation, and asset protection plans for high net worth individuals. Subsequently, Mr Wong worked at Credit Agricole (Suisse), Hong Kong, where he advised the bank’s clients on wealth management.
Mr Wong holds a Bachelor of Commerce from the University of Calgary, Alberta, Canada.
Mr Chen Bing Chuen, Albert
Mr Albert Chen was appointed as a Nonindependent Non-Executive Director of the Company on April 29, 2016. Currently, Mr Chen serves as Chief Financial Officer and Director of NYSE-listed China Cord Blood Corporation (“CCBC”). He is in charge of CCBC’s finance-related matters, including accounting and budget planning. He is also involved in CCBC’s corporate structuring and development, including mergers and acquisitions, and investment in foreign healthcare companies. Mr Chen played an important role in the acquisition of Nuoya (“Guangdong Province Cord Blood Bank”) and investments in Cordlife (“Life Corporation Limited and Cordlife Group Limited”). He had served as the corporate finance vice president of Golden Meditech Holdings Limited (“Golden Meditech”) since March 2005. Prior to joining Golden Meditech, Mr Chen worked in a number of financial institutions, including Salomon Smith Barney, DBS Vickers Securities and UOB Kay Hian in Hong Kong. During his employment as an analyst in UOB Kay Hian from 2003 to March 2005, he was a senior analyst specialising in the pharmaceutical and healthcare industries and was ranked as one of the best analysts for small cap companies in the region in a poll conducted by Asia Money among brokers in 2003.
Mr Chen is a CFA charterholder. He received his Bachelor’s degree in Commerce from Queen’s University, Canada, School of Business in 1999 with a major in Finance and Accounting.
Ms Christine Wong
Ms Christine Wong was appointed as a Non-Independent Non-Executive Director of the Company on November 1, 2016.
Ms Wong is the Senior Investment Director of Kunlum Investment Holding Limited ("Kunlum") since November 2015. Prior to joining Kunlum, Ms Wong was the Managing Director at CBW Consulting, Inc. for 10 years, a consulting firm focusing on United States-China relations and business projects.
Ms Wong obtained her Bachelor degree in Business Administration from Hofstra University.
Dr Wang Tongyan
Dr Wang Tongyan was appointed as a Non-Independent Non-Executive Director of the Company on May 4, 2017.
Dr Wang has over 22 years of experience in the pharmaceutical industry, specialising in market management. She is currently the Vice President of Sanpower Group where she takes charge of biomedical group strategies and medical industry management. Dr Wang holds various public posts including her position as the Vice President of China Pharmaceutical Industry Association. Prior to joining Sanpower Group, she was the Vice President of Image Innovation at Nanchang China Sciences Group and Chief Operating Officer at CSG Jiufeng Mobile Health Care Co., Ltd. Dr Wang also previously served as the Vice President of Janssen Pharmaceutical Co., Ltd of US Johnson & Johnson ("JNJ") Group. During her career at JNJ, she was the sales director and Chief Marketing Officer. She also held various leadership positions within JNJ Group, handling business division management, market development and government affairs.
Dr Wang has a PhD from University of Lisbon in theoretical research. She also graduated with a Master in Business Administration and a Bachelor of Clinical Medicine from Xian Jiaotong University.